Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose
AE Fiore, CN Shapiro, K Sabin, K Labonte… - The Pediatric …, 2003 - journals.lww.com
AE Fiore, CN Shapiro, K Sabin, K Labonte, K Darling, D Culver, BP Bell, HS Margolis
The Pediatric infectious disease journal, 2003•journals.lww.comBackground. Infants with passively transferred maternal antibody (PMA) to hepatitis A virus
(HAV) have lower concentrations of antibody to HAV (anti-HAV) after vaccination. We
examined the effect of PMA on persistence of anti-HAV and on immune memory. Methods.
We measured anti-HAV concentrations of 6-year-old children who had responded to a three
dose hepatitis A vaccine series at ages 2, 4 and 6 months. Group 1 children were born to
anti-HAV-negative women; Group 2 children had anti-HAV-positive mothers and PMA at 2 …
(HAV) have lower concentrations of antibody to HAV (anti-HAV) after vaccination. We
examined the effect of PMA on persistence of anti-HAV and on immune memory. Methods.
We measured anti-HAV concentrations of 6-year-old children who had responded to a three
dose hepatitis A vaccine series at ages 2, 4 and 6 months. Group 1 children were born to
anti-HAV-negative women; Group 2 children had anti-HAV-positive mothers and PMA at 2 …
Abstract
Background.
Infants with passively transferred maternal antibody (PMA) to hepatitis A virus (HAV) have lower concentrations of antibody to HAV (anti-HAV) after vaccination. We examined the effect of PMA on persistence of anti-HAV and on immune memory.
Methods.
We measured anti-HAV concentrations of 6-year-old children who had responded to a three dose hepatitis A vaccine series at ages 2, 4 and 6 months. Group 1 children were born to anti-HAV-negative women; Group 2 children had anti-HAV-positive mothers and PMA at 2 months of age. Children without detectable antibody at 6-year follow-up were offered a booster dose [360 enzyme-linked immunosorbent units (ELU)]. An anamnestic response was defined as a postbooster anti-HAV concentration of≥ 400 mIU/ml.
Results.
At follow-up, before the booster dose, Group 1 subjects had a higher geometric mean concentration (50 mIU/ml vs.
Lippincott Williams & Wilkins